Baseline characteristics of treated patients
| Baseline characteristics at cilta-cel infusion . | N = 10 . |
|---|---|
| Sex | 4 females, 6 males |
| Age, median (range), y | 63 (49-75) |
| Penta-refractory | 7 |
| High-risk cytogenetics | 7 |
| Double-hit cytogenetics | 5 |
| Extramedullary disease | 4 |
| Prior lines, median (range) | 7 (5-12) |
| BCMA expression | 8/8 (2 missing) |
| Treatment-related, median (range) | |
| Time between diagnosis and ide-cel infusion, y | 5.8 (2.5-10.0) |
| PFS after ide-cel, mo | 14.9 (1.7-40.4) |
| Time between ide-cel and cilta-cel infusion, y | 1.9 (1.2-4.0) |
| Number of therapies between CAR T-cell products | 1 (0-3) |
| CAR T-cell therapy expansion, Cmax (PCR) cp/10E6 WBC | 248 000 (27 500-1 410 000) |
| Disease status at cilta-cel infusion | 4 PD, 3 SD, 2 PR, 1 VGPR |
| Feasibility & toxicity | |
| Vein-to-vein ide-cel, median (range), d | 53.5 (45-88) |
| Vein-to-vein cilta-cel, median (range), d | 61 (46-110) |
| CRS ide-cel | I° (n = 5), II° (n = 5) |
| ICANS ide-cel | 0 |
| CRS cilta-cel | I° (n = 3), II° (n = 3) |
| ICANS cilta-cel | 0 |
| Other neurotoxicity | 1 trochlear palsy |
| In-hospital ide-cel, median (range), d | 17 (10-23) |
| In-hospital cilta-cel, median (range), d | 11 (0-16) |
| Baseline characteristics at cilta-cel infusion . | N = 10 . |
|---|---|
| Sex | 4 females, 6 males |
| Age, median (range), y | 63 (49-75) |
| Penta-refractory | 7 |
| High-risk cytogenetics | 7 |
| Double-hit cytogenetics | 5 |
| Extramedullary disease | 4 |
| Prior lines, median (range) | 7 (5-12) |
| BCMA expression | 8/8 (2 missing) |
| Treatment-related, median (range) | |
| Time between diagnosis and ide-cel infusion, y | 5.8 (2.5-10.0) |
| PFS after ide-cel, mo | 14.9 (1.7-40.4) |
| Time between ide-cel and cilta-cel infusion, y | 1.9 (1.2-4.0) |
| Number of therapies between CAR T-cell products | 1 (0-3) |
| CAR T-cell therapy expansion, Cmax (PCR) cp/10E6 WBC | 248 000 (27 500-1 410 000) |
| Disease status at cilta-cel infusion | 4 PD, 3 SD, 2 PR, 1 VGPR |
| Feasibility & toxicity | |
| Vein-to-vein ide-cel, median (range), d | 53.5 (45-88) |
| Vein-to-vein cilta-cel, median (range), d | 61 (46-110) |
| CRS ide-cel | I° (n = 5), II° (n = 5) |
| ICANS ide-cel | 0 |
| CRS cilta-cel | I° (n = 3), II° (n = 3) |
| ICANS cilta-cel | 0 |
| Other neurotoxicity | 1 trochlear palsy |
| In-hospital ide-cel, median (range), d | 17 (10-23) |
| In-hospital cilta-cel, median (range), d | 11 (0-16) |
Data points are related to cilta-cel if not mentioned otherwise.
Cmax, maximum concentration in copies per white blood cells (WBC); CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome; PCR, polymerase chain reaction; PD, progressive disease; PR, partial remission; SD, stable disease; VGPR, very good partial response.